Bachem Holding AG Stock Price
- 4 Narratives written by author
- 0 Comments on narratives written by author
- 34 Fair Values set on narratives written by author
BANB Community Narratives
Bachem Holding - The Purest Public Peptide Play?
Building K Production Will Serve Peptide And Oligonucleotide Therapies
Expanding Facilities And Secular Trends Will Fuel Peptide Therapeutics Demand
Bachem Holding - The Purest Public Peptide Play?
View narrativeStrict Global Regulation And Rising Costs Will Impede Peptide Capacity
View narrativeBuilding K Production Will Serve Peptide And Oligonucleotide Therapies
View narrativeExpanding Facilities And Secular Trends Will Fuel Peptide Therapeutics Demand
View narrativeTrending Discussion
No trending discussion available.
Recently Updated Narratives
Bachem Holding - The Purest Public Peptide Play?
BANB: New Manufacturing Partnership Will Raise Execution Risk And Limit Future Upside
BANB: Future Execution At New Facility Is Expected To Sustain Fair Value
Snowflake Analysis
Bachem Holding AG Key Details
- 1.99
- 27.00%
- 21.02%
- 14.4%
About BANB
- Founded
- 1971
- Employees
- 2725
- CEO
- Website
View website
Bachem Holding AG, together with its subsidiaries, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. It engages in the development, production, and regulatory support of peptide active pharmaceutical ingredients, such as peptide and oligonucleotide new chemical entities (NCEs). The company also offers commercial NCEs and generics; and project management, quality and regulatory, analytical, good manufacturing practice production, research grade production, and supply and vertical integration services. Bachem Holding AG was incorporated in 1971 and is headquartered in Bubendorf, Switzerland. Bachem Holding AG operates as a subsidiary of Ingro Finanz AG.